The activity of several halogenated copper (II) complexes of 4-chloro-3-nitrophenylthiourea derivatives has been tested against Mycobacterium tuberculosis strains and strains of non-tuberculous mycobacteria. The compounds were 2–16 times more potent than current TB-drugs against multidrug-resistant M. tuberculosis 210. The 3,4-dichlorophenylthiourea complex (5) was equipotent to ethambutol (EMB) towards M. tuberculosis H₃₇Rv and 192 strains. All derivatives acted 2–8 times stronger than isoniazid (INH) against nontuberculous isolates. In the presence of chosen coordinates, the 2–64 times reduction of MIC values of standard drugs was denoted. The synergistic interaction was found between the complex 4 and rifampicin (RMP), and additivity of 1–5, 8 in pairs with EMB and/or streptomycin (SM) against M. tuberculosis 800 was established. All coordination compounds in combination with at least one drug showed additive activity towards both H₃₇Rv and 192 isolates. In 67% incidences of indifference, the individual MIC of a drug decreased 2-16-fold. One can conclude that the novel thiourea chelates described here are potent hits for further developments of new agents against tuberculosis.

已经测试了几种 4-氯-3-硝基苯基硫脲衍生物的卤化铜 (II) 配合物对结核分枝杆菌菌株和非结核分枝杆菌菌株的活性。这些化合物对抗多重耐药结核分枝杆菌210 的效力比现有结核病药物强 2-16 倍。3,4-二氯苯基硫脲复合物 ( 5 ) 对结核分枝杆菌H ₃₇ Rv 和 192 菌株的作用与乙胺丁醇 (EMB) 等效。。所有衍生物对非结核菌的作用比异烟肼 (INH) 强 2-8 倍。在存在选定坐标的情况下，标准药物的 MIC 值降低了 2-64 倍。在复合物4和利福平(RMP)之间发现了协同相互作用，并且建立了1-5、8与EMB和/或链霉素(SM)配对对抗结核分枝杆菌800的加和性。所有与至少一种药物组合的配位化合物均对 H ₃₇ Rv 和 192 分离株显示出附加活性。在 67% 的无差异发生率中，药物的个体 MIC 降低了 2-16 倍。人们可以得出结论，这里描述的新型硫脲螯合物对于进一步开发抗结核病新药来说是一个有力的打击。